Mitobridge Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Mitobridge Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014304
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Mitobridge Inc (Mitobridge), formerly Mitokyne, Inc. is a drug development company that discovers and develops small molecule therapeutics. The company offers products that enhance the mitochondrial functions. It develops therapies for rare diseases and then expand into more common diseases. Mitobridge utilizes screening platform to identify and develop novel therapeutics. The company holds expertise in the areas of mitochondrial genetic diseases, musculoskeletal, kidney and neurodegenerative disorders as well as diseases and conditions of aging. It works in collaboration with companies in the field of mitochondrial biology and medicine. Mitobridge is headquartered in Cambridge, Massachusetts, the US.

Mitobridge Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Mitobridge Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Mitobridge Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Mitobridge Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Mitobridge Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Mitobridge Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Mitobridge Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Mitokyne Raises US$45 Million In Series A Financing 10
Partnerships 11
Astellas Pharma Enters Into R&D Agreement With Mitokyne For Drug Discovery 11
Licensing Agreements 13
Mitobridge Enters into Licensing Agreement with Ecole Polytechnique Federale de Lausanne 13
Mitobridge Enters into Licensing Agreement with Salk Institute for Biological Studies 14
Mitobridge Inc – Key Competitors 15
Mitobridge Inc – Key Employees 16
Mitobridge Inc – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Clinical Trials 18
Nov 06, 2017: Mitobridge Presents Preclinical Data Demonstrating Beneficial Effects of PPARd Modulators in Acute Kidney Injury at American Society of Nephrology Annual Meeting 18
Aug 08, 2017: Mitobridge’s Novel Treatment Approach for Duchenne Muscular Dystrophy Advances into Clinical Development 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
Mitobridge Inc, Pharmaceuticals & Healthcare, Key Facts 2
Mitobridge Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Mitobridge Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Mitobridge Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Mitobridge Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Mitobridge Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Mitokyne Raises US$45 Million In Series A Financing 10
Astellas Pharma Enters Into R&D Agreement With Mitokyne For Drug Discovery 11
Mitobridge Enters into Licensing Agreement with Ecole Polytechnique Federale de Lausanne 13
Mitobridge Enters into Licensing Agreement with Salk Institute for Biological Studies 14
Mitobridge Inc, Key Competitors 15
Mitobridge Inc, Key Employees 16

★海外企業調査レポート[Mitobridge Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Hankyu Hanshin Holdings, Inc.:企業の戦略・SWOT・財務情報
    Hankyu Hanshin Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Hankyu Hanshin Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • TransAlta Corporation:企業の戦略・SWOT・財務分析
    TransAlta Corporation - Strategy, SWOT and Corporate Finance Report Summary TransAlta Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • TSO3 Inc (TOS):企業の財務・戦略的SWOT分析
    TSO3 Inc (TOS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Global Bio-chem Technology Group Company Limited (809):企業の財務・戦略的SWOT分析
    Global Bio-chem Technology Group Company Limited (809) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s …
  • Sakai Chemical Industry Co Ltd (4078):企業の財務・戦略的SWOT分析
    Sakai Chemical Industry Co Ltd (4078) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Entergy Corporation:企業の戦略・SWOT・財務情報
    Entergy Corporation - Strategy, SWOT and Corporate Finance Report Summary Entergy Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Votorantim Energia Ltda.:企業の戦略的SWOT分析
    Votorantim Energia Ltda. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Hargreaves Lansdown PLC:企業の戦略・SWOT・財務情報
    Hargreaves Lansdown PLC - Strategy, SWOT and Corporate Finance Report Summary Hargreaves Lansdown PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • iBio Inc (IBIO):医療機器:M&Aディール及び事業提携情報
    Summary iBio Inc (iBio) is a biotechnology company that develops and manufactures plant made pharmaceutical products. The company provides products such as biotherapeutics and vaccines. It has its applications in ibiolaunch platform, which is a transformative technology for the production of monoclo …
  • NETGEAR Inc (NTGR):企業の財務・戦略的SWOT分析
    NETGEAR Inc (NTGR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Huron Consulting Group Inc:企業のM&A・事業提携・投資動向
    Huron Consulting Group Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Huron Consulting Group Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Mitsui Fudosan Co Ltd (8801):企業の財務・戦略的SWOT分析
    Mitsui Fudosan Co Ltd (8801) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Fujisoft Inc (9749):企業の財務・戦略的SWOT分析
    Fujisoft Inc (9749) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Fujikura Ltd.:企業の戦略・SWOT・財務情報
    Fujikura Ltd. - Strategy, SWOT and Corporate Finance Report Summary Fujikura Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Steinhoff International Holdings NV (SNH):企業の財務・戦略的SWOT分析
    Steinhoff International Holdings NV (SNH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • ShinMaywa Industries, Ltd.:企業の戦略・SWOT・財務情報
    ShinMaywa Industries, Ltd. - Strategy, SWOT and Corporate Finance Report Summary ShinMaywa Industries, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Engie SA (ENGI)-エネルギー分野:企業M&A・提携分析
    Summary Engie S.A. (Engie), formerly GDF Suez S.A., is an electric utility, which generates and distributes electricity and natural gas. It generates electricity using various sources including hydro, wind, solar, biomass, geothermal, nuclear, coal and fuel oil. The company supplies, distributes, tr …
  • Komeri Co Ltd:企業の戦略・SWOT・財務分析
    Komeri Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Komeri Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Lantern Pharma Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Lantern Pharma Inc (Lantern Pharma) is a clinical stage pharmaceutical company that discovers and develops therapies for various cancer types. The company’s pipeline products Irofulven-1 and Irofulven-2 are non-hormone, non-chemotherapy, next-generation DNA damage repair inhibitors. Its othe …
  • Kalpataru Power Transmission Ltd:企業の戦略・SWOT・財務情報
    Kalpataru Power Transmission Ltd - Strategy, SWOT and Corporate Finance Report Summary Kalpataru Power Transmission Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆